Ophthalmology-focused bio-pharmaceutical company OKYO Pharma said on Tuesday it has applied to the UK's Financial Conduct Authority and London Stock Exchange Plc to delist from the LSE's main market.

The delisting will have no impact on the company's American Depositary Shares, which are traded on the Nasdaq, the company said in a statement. (Reporting by Radhika Anilkumar in Bengaluru; Editing by Sherry Jacob-Phillips)